Women's Health Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Breast Cancer
Data: Tarvacin equivalent plus docetaxel inhibits breast tumor growth by 93%
June 16th, 2005
Peregrine Pharmaceuticals, Inc., (PPHM), announced that a research article titled "A Monoclonal Antibody that Binds Anionic Phospholipids on Tumor Blood Vessels Enhances the Antitumor Effect of Docetaxel on Human Breast Tumors in Mice" was published in the May 15, 2005, issue of Cancer Research. The published report shows that 3G4 (a murine equivalent of the company's Tarvacin monoclonal antibody) in combination with docetaxel results in a 93% inhibition of human breast cancer growth in mouse models. The researchers found that docetaxel increases the exposure of the 3G4 target on tumor blood vessels but not healthy tissue. Patient enrollment in a Tarvacin phase I...
Source: Women's Health Weekly (2005-06-16)
|
